Trial Profile
Clinical pharmacology study to evaluate the pharmacokinetics, safety and efficacy of multi-targetted tyrosine kinase inhibitor regorafenib in Japanese patients with advanced colorectal cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Feb 2020 Results published in the Clinical Pharmacology and Therapeutics.
- 03 Apr 2019 Status changed to completed as per results presented at the 110th Annual Meeting of the American Association for Cancer Research
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research